CP
MRNA icon

Castleview Partners’s Moderna MRNA Stock Holding History

Castleview Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-56
Closed -$6.8K – 734
2023
Q2 		$6.8K Hold
56
– – 0.01% 470
2023
Q1 		$8.6K Hold
56
– – 0.01% 444
2022
Q4 		$10.1K Hold
56
– – 0.01% 369
2022
Q3 		$7K Sell
56
-10,628
-99% -$1.61M 0.01% 421
2022
Q2 		$663K Buy
10,684
+10,649
+30,426% +$1.52M 0.53% 35
2022
Q1 		$6K Buy
+35
New +$5.89K ﹤0.01% 557
2021
Q2 		$8K Buy
+35
New +$6.25K ﹤0.01% 742

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Castleview Partners's MRNA Position: Q3 2023 in Review

Castleview Partners sold out of Moderna (MRNA) in Q3 2023, closing a stake of 56 shares — an estimated $6.8K sold.

Castleview Partners first reported a position in MRNA in Q2 2021 and held it in 7 quarters. The position peaked at $663K in Q2 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Castleview Partners reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Castleview Partners sold 56 Moderna shares in Q3 2023, an estimated $6.8K.
  • Castleview Partners first reported a position in Moderna in Q2 2021 and held it in 7 quarters.
  • Castleview Partners's Moderna position peaked at $663K in Q2 2022.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Castleview Partners's 13F filing for Q3 2023, filed 26 Oct 2023.